Attached files

                              For immediate release

                         Global Green, Inc. Strengthens
               Board of Directors and Management Team and Receives
       Advance in Funds from Chairman and CEO to Support Company's Growth
--------------------------------------------------------------------------------

             Latest initiatives to support corporate growth strategy


Tallahassee,  Fla - January 16, 2013 - Global  Green,  Inc.  (OTCBB:GOGC)  today
announced  that Konky  Sotomayor,  DVM, the developer of  Salmogenics,  has been
appointed  to the Board of Directors  and to the position  within the Company of
Chief Scientist and Vice President - R&D.

Global Green also  announced  that Dr.  Mehran  Ghazvini,  Chairman and CEO, has
advanced the Company $300,000 to support the Company's growth.  This amount will
be paid back to Dr.  Ghazvini at a future date in  preferred  shares,  cash or a
combination of both.
Dr.  Sotomayor  graduated  with honors as a Doctor in  Veterinary  Medicine  and
Zootechny  in the  Veterinary  Medicine  Faculty  from the State  University  of
Guayaquil in Ecuador.  He attended the prestigious  Lantanisbruk  Universitet in
Uppsala,  Sweden,  renowned for their International Science Program. The program
assists  countries in strengthening  their domestic research capacity within the
chemical,  physical and the mathematical  sciences.  Dr. Sotomayor has worked in
private  laboratory-managing  research  and  development  positions  since  1979
including being a principal of Nutritional  Health Institute  Laboratories,  LLC
("NHIL"). NHIL is Global Green's research affiliate and majority shareholder. He
has  extensive   experience  in  isolation  of  infectious  disease  agents  and
manufacturing of the corresponding vaccines.

Dr. Ghazvini  stated,  "Dr.  Sotomayor,  the developer of the  Salmogenics,  the
Company`s  patented  Salmonella  vaccine,  is a perfect addition to our Board of
Directors.  His character,  strong  background and an extensive  track record in
animal  infectious  disease  research and  laboratory  diagnostics  makes him an
important asset. As we execute our core strategy and work to build a pipeline of
high value drug discovery and development  programs to deliver tangible results,
Dr. Sotomayor's leadership as Chief Scientist and VP - R&D will be critical."

The  Salmogenics  vaccine is in its last stages of testing and trials before the
final United States Department of Agriculture/Food Safety and Inspection Service
("USDA") approval for its commercial application.







Global Green,  Inc. is a green  pharmaceutical  company committed to identifying
technology platforms and commercializing products that contain natural organisms
that  are  not  genetically  modified,   utilizing   pharmaceutical   standards.
Salmogenics, the Company's flagship product, was developed by Nutritional Health
Institute  Laboratories,  LLC, research affiliate and majority shareholder.  The
vaccine is currently in the final stage of the USDA approval  process.  For more
information, visit www.globalgreeninc.org.

Forward-Looking Statement
This press release may contain  certain  forward-looking  statements  within the
meaning of Section 27A of the  Securities  Act of 1933, as amended,  and Section
21E of the Securities Exchange Act of 1934, as amended.  Investors are cautioned
that such  forward-looking  statements  involve risks and  uncertainties,  which
include  among  others,  the  inherent  uncertainties  associated  with  smaller
reporting  companies,  including without  limitation,  other risks detailed from
time to time in the Company's  periodic  reports filed with the  Securities  and
Exchange Commission.

Contact:
Pam Lagano
plagano@globalgreeninc.org
727.480.308